Unibest

Pharmaceutical intermediates

Letermovir Intermediates

4 pharmaceutical intermediates for Letermovir. Indication: Cytomegalovirus Infection.

Submit a ProjectAll intermediates

About Letermovir

Originator
Aicuris
Indication
Cytomegalovirus Infection
Approved Date
11/08/2017
DS/DP
06/05/2026

Available intermediates

4 intermediates currently listed for Letermovir. Request specifications, documentation or a quotation for any item below.

Letermovir intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-Propenoic acid, 3-[3-fluoro-2-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-, methyl ester, (2E)-917389-26-5//
2-Propenoic acid, 3-[3-fluoro-2-[(phenoxycarbonyl)amino]phenyl]-, methyl ester, (2E)-1791412-01-5//
2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl) -2-oxo-1,2,3,4-tetrahydroquinazolin-4-yl) acetic acid methyl ester917389-21-0//
1-(3-Methoxyphenyl)Piperazine Hydrochloride16015-70-6//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Letermovir?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →